In contrast, IL-22 expression in BALF was significantly elevated in tumor site (271.1 ± 67.38 pg/ml) compared within nontumor site (68.67 ± 16.39 pg/ml, P<0.0001, Figure 2B) in lung adenocarcinoma patients. This evidence concerns the gene IL22 and lung adenocarcinoma.